PortalPublikationenImpact of allogeneic stem cell transplantation on survival o...

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis

Standard

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis. / Kröger, Nicolaus; Giorgino, Toni; Scott, Bart L; Ditschkowski, Markus; Alchalby, Haefaa; Cervantes, Francisco; Vannucchi, Alessandro; Cazzola, Mario; Morra, Enrica; Zabelina, Tatjana; Maffioli, Margherita; Pereira, Arturo; Beelen, Dietrich; Deeg, H Joachim; Passamonti, Francesco.

in: BLOOD, Jahrgang 125, Nr. 21, 17.03.2015, S. 3347-3350.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kröger, N, Giorgino, T, Scott, BL, Ditschkowski, M, Alchalby, H, Cervantes, F, Vannucchi, A, Cazzola, M, Morra, E, Zabelina, T, Maffioli, M, Pereira, A, Beelen, D, Deeg, HJ & Passamonti, F 2015, 'Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis', BLOOD, Jg. 125, Nr. 21, S. 3347-3350. https://doi.org/10.1182/blood-2014-10-608315

APA

Kröger, N., Giorgino, T., Scott, B. L., Ditschkowski, M., Alchalby, H., Cervantes, F., Vannucchi, A., Cazzola, M., Morra, E., Zabelina, T., Maffioli, M., Pereira, A., Beelen, D., Deeg, H. J., & Passamonti, F. (2015). Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis. BLOOD, 125(21), 3347-3350. https://doi.org/10.1182/blood-2014-10-608315

Vancouver

Kröger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis. BLOOD. 2015 Mär 17;125(21):3347-3350. https://doi.org/10.1182/blood-2014-10-608315

Bibtex

@article{92a4a543914344f5b0a1d447fda31dee,
title = "Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis",
abstract = "Allogeneic hematopoietic stem cell transplantation (ASCT) is the only curative option for patients with primary myelofibrosis (PMF), but information on the net advantage over conventional therapies is lacking. Using an ad hoc statistical analysis, we determined outcomes in 438 patients younger than 65 years at diagnosis who received ASCT (n=190) or conventional therapies (n=248). Among patients with low risk by Dynamic International Prognostic Scoring System (DIPSS) prognostic model the relative risk of dying after receiving ASCT versus those treated with non-transplant modalities was 5.6 (95% CI: 1.7-19; P=0.0051); for intermediate-1 risk it was 1.6 (95% CI: 0.79-3.2; P=0.19), for intermediate-2, 0.55 (95% CI: 0.36-0.83; P=0.005), and for high risk 0.37 (95% CI: 0.21-0.66; P=0.0007). Thus, patients with intermediate-2 or high risk PMF clearly benefit from ASCT. Patients at low risk should receive non-transplant therapy, while individual counseling is indicated for patients at intermediate-1 risk.",
author = "Nicolaus Kr{\"o}ger and Toni Giorgino and Scott, {Bart L} and Markus Ditschkowski and Haefaa Alchalby and Francisco Cervantes and Alessandro Vannucchi and Mario Cazzola and Enrica Morra and Tatjana Zabelina and Margherita Maffioli and Arturo Pereira and Dietrich Beelen and Deeg, {H Joachim} and Francesco Passamonti",
note = "Copyright {\textcopyright} 2015 American Society of Hematology.",
year = "2015",
month = mar,
day = "17",
doi = "10.1182/blood-2014-10-608315",
language = "English",
volume = "125",
pages = "3347--3350",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "21",

}

RIS

TY - JOUR

T1 - Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis

AU - Kröger, Nicolaus

AU - Giorgino, Toni

AU - Scott, Bart L

AU - Ditschkowski, Markus

AU - Alchalby, Haefaa

AU - Cervantes, Francisco

AU - Vannucchi, Alessandro

AU - Cazzola, Mario

AU - Morra, Enrica

AU - Zabelina, Tatjana

AU - Maffioli, Margherita

AU - Pereira, Arturo

AU - Beelen, Dietrich

AU - Deeg, H Joachim

AU - Passamonti, Francesco

N1 - Copyright © 2015 American Society of Hematology.

PY - 2015/3/17

Y1 - 2015/3/17

N2 - Allogeneic hematopoietic stem cell transplantation (ASCT) is the only curative option for patients with primary myelofibrosis (PMF), but information on the net advantage over conventional therapies is lacking. Using an ad hoc statistical analysis, we determined outcomes in 438 patients younger than 65 years at diagnosis who received ASCT (n=190) or conventional therapies (n=248). Among patients with low risk by Dynamic International Prognostic Scoring System (DIPSS) prognostic model the relative risk of dying after receiving ASCT versus those treated with non-transplant modalities was 5.6 (95% CI: 1.7-19; P=0.0051); for intermediate-1 risk it was 1.6 (95% CI: 0.79-3.2; P=0.19), for intermediate-2, 0.55 (95% CI: 0.36-0.83; P=0.005), and for high risk 0.37 (95% CI: 0.21-0.66; P=0.0007). Thus, patients with intermediate-2 or high risk PMF clearly benefit from ASCT. Patients at low risk should receive non-transplant therapy, while individual counseling is indicated for patients at intermediate-1 risk.

AB - Allogeneic hematopoietic stem cell transplantation (ASCT) is the only curative option for patients with primary myelofibrosis (PMF), but information on the net advantage over conventional therapies is lacking. Using an ad hoc statistical analysis, we determined outcomes in 438 patients younger than 65 years at diagnosis who received ASCT (n=190) or conventional therapies (n=248). Among patients with low risk by Dynamic International Prognostic Scoring System (DIPSS) prognostic model the relative risk of dying after receiving ASCT versus those treated with non-transplant modalities was 5.6 (95% CI: 1.7-19; P=0.0051); for intermediate-1 risk it was 1.6 (95% CI: 0.79-3.2; P=0.19), for intermediate-2, 0.55 (95% CI: 0.36-0.83; P=0.005), and for high risk 0.37 (95% CI: 0.21-0.66; P=0.0007). Thus, patients with intermediate-2 or high risk PMF clearly benefit from ASCT. Patients at low risk should receive non-transplant therapy, while individual counseling is indicated for patients at intermediate-1 risk.

U2 - 10.1182/blood-2014-10-608315

DO - 10.1182/blood-2014-10-608315

M3 - SCORING: Journal article

C2 - 25784679

VL - 125

SP - 3347

EP - 3350

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 21

ER -